Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
FORTE trial results: KRd with or without transplantation in newly diagnosed myeloma according to risk status

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.06.19
Views: 945
Rating:

Dr Francesca Gay - University Hospital City of Health and Science of Turin, Turin, Italy

Dr Francesca Gay talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the results from the randomised FORTE trial which looked at the use of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma and evaluated according to risk status.

She reports that the rate of response and of minimal residual disease negativity between the two arms was similar but that patients with standard risk had a higher rate of stringent CR and minimal residual disease negativity.

Dr Gay adds that high risk patients receiving transplant had a higher rate of 1 year sustained minimal residual disease negativity than patients who did not.

She explains that this could be why patients who did not receive transplant have a higher rate of relapse compared with patients who received transplant.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation